TPST on Nasdaq

Tempest Therapeutics, Inc.

We are a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with ABVC BIOPHARMA, INC., Immuneering Corp or Vyome Holdings, Inc, or pick any stock.

  • TickerTPST on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersBrisbane, California1
  • Incorporated inDE2
  • Business address2000 Sierra Point Parkway, Suite 400, Brisbane, Ca 940052
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates. In February 2026, we expanded our pipeline through a strategic transaction under which we acquired rights to a portfolio of dual-targeting chimeric antigen receptor T-cells (“CAR-T”) product candidates with the potential to treat certain blood cancers, solid tumors and immunology indications, including TPST-2003, an autologous CD19/B-cell maturation antigen (“BCMA”) CAR-T therapy currently in clinical development for relapsed or refractory multiple myeloma (“rrMM”).3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456789-$26.6M in 2025−41% since 2019
-$60.0M-$40.0M-$20.0M02019: -$45.4M-$45.4M20192020: -$19.3M-$19.3M2020−57%2021: -$27.0M-$27.0M2021+40%2022: -$34.6M-$34.6M2022+28%2023: -$29.2M-$29.2M2023−16%2024: -$42.0M-$42.0M2024+44%2025: -$26.6M-$26.6M2025−37%
Net income456789-$26.3M in 2025−41% since 2019
-$60.0M-$40.0M-$20.0M02019: -$44.6M-$44.6M20192020: -$19.2M-$19.2M2020−57%2021: -$28.3M-$28.3M2021+47%2022: -$35.7M-$35.7M2022+26%2023: -$29.5M-$29.5M2023−17%2024: -$41.8M-$41.8M2024+42%2025: -$26.3M-$26.3M2025−37%

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
Research and development$12.6M$28.5M
General and administrative$14.0M$13.6M
Operating loss-$26.6M-$42.0M
Interest expense-$207.0K-$1.3M
Interest income and other income (expense), net$520.0K$1.5M
Other income (expense), net$313.0K$183.0K
Provision for income taxes$0$0
Net loss-$26.3M-$41.8M
Net loss per share of common stock and pre-funded warrants, basic-$6.33-$19.50
Net loss per share of common stock and pre-funded warrants, diluted-$6.33-$19.50
Weighted-average shares used in computing basic net loss per share4.1M shares2.1M shares
Weighted-average shares of common stock and pre-funded warrants outstanding, diluted4.1M shares2.1M shares

Compare Tempest Therapeutics, Inc. with another company

Leadership

Who has led Tempest Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Christopher A. Kroeger2017–2018
  2. Julia C. Owens2018–2020
  3. Louis J. Arcudi2021
  4. Stephen R. Brady2021–2026
  5. Matthew Angel2026–now

Chair

  1. Julia C. Owens2021

President

  1. Arthur Tzianabos2014–2015
  2. Julia C. Owens2018–2020
  3. Louis J. Arcudi2021
  4. Thomas W. Dubensky2021–2023
  5. Stephen R. Brady2023–2026
  6. Matthew Angel2026–now

Chief financial officer

  1. Christophe Couturier2016–2017
  2. Louis J. Arcudi2018–2020
  3. Jennifer Lynn Minai-Azary2021
  4. Nicholas Maestas2025–now

Chief operating officer

  1. Christopher A. Bleck2012
  2. Alison Francis Lawton2013
  3. Paul W.d. Chapman2016
201520202025
Board members and other officers (48)

Former names

  • Millendo Therapeutics, Inc.Nov 15, 2018 to Jul 1, 20212
  • OvaScience, Inc.Apr 9, 2012 to Dec 6, 20182

Timeline

  1. Feb 6, 2026New chief executive Matthew Angel becomes CEO13
  2. Jun 29, 2021New chief executive Stephen R. Brady becomes CEO15
  3. Mar 2, 2021New chief executive Louis J. Arcudi becomes CEO14
  4. Dec 11, 2018New chief executive Julia C. Owens becomes CEO16
  5. Sep 11, 2017New chief executive Christopher A. Kroeger becomes CEO17

Filings

272 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 70 major events, 68 insider forms, 22 large holders, 4 private raises, 86 other. The latest 20:

  1. Oct 14, 2026D EDGAR
  2. Oct 2, 20264 EDGAR
  3. Oct 2, 20263 EDGAR
  4. Oct 2, 2026424B3 PROSPECTUS EDGAR
  5. Oct 1, 2026EFFECT EDGAR
  6. Sep 28, 20268-K CURRENT REPORT EDGAR
  7. Sep 25, 2026S-3 REGISTRATION STATEMENT EDGAR
  8. Sep 17, 20268-K EDGAR
  9. Sep 16, 2026DEFA14A EDGAR
  10. Sep 16, 20268-K EDGAR
  11. Sep 15, 20268-K EDGAR
  12. Sep 1, 2026424B3 EDGAR
  13. Aug 31, 2026EFFECT EDGAR
  14. Aug 27, 2026CORRESP EDGAR
  15. Aug 27, 2026UPLOAD EDGAR
  16. Aug 24, 20268-K EDGAR
  17. Aug 21, 2026S-1 EDGAR
  18. Aug 18, 2026DEFA14A EDGAR
  19. Aug 18, 20268-K EDGAR
  20. Aug 13, 202610-Q EDGAR

The 272 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

10 open-market trades by officers, directors and large owners since October 2021: 8 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 24, 2026Angel MatthewCEO and PresidentBuy231,482$2.16$500.0KForm 4
Mar 24, 2026Angel MatthewCEO and PresidentBuy231,482$2.16$500.0KForm 4
Aug 12, 2024Versant Venture Capital VI, L.P.10% ownerSale387,999$1.10$426.8KForm 4
Aug 8, 2024Versant Venture Capital VI, L.P.10% ownerSale400,000$1.35$540.0KForm 4
Jul 3, 2024Brady Stephen RPresident and CEOBuy35,000$2.11$73.8KForm 4
Jul 2, 2024Whiting SamuelChief Medical OfficerBuy4,672$2.13$10.0KForm 4
Jun 28, 2024Trojanowski JustinCorporate ControllerBuy7,500$2.16$16.2KForm 4
Apr 29, 2022Woiwode ThomasDirectorBuy2,118,644$2.36$5.0MForm 4
Jan 7, 2022Dubensky Thomas W.PresidentBuy2,000$4.78$9.6KForm 4
Jan 6, 2022Whiting SamuelChief Medical OfficerBuy1,700$4.80$8.2KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. May 29, 2026Raised $4.1 million in a private offering of equity Form D: 1 investor so far Form D
  2. Mar 20, 2026Raised $2 million in a private offering of equity Form D: 3 investors so far Form D
  3. Apr 26, 2022Raised $15 million in a private offering of equity Form D: 2 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Sabby Management, LLC511,286$567.5K4.7%+493,430
Vanguard Capital Management LLC233,888$259.6K0.0%No change
Geode Capital Management, LLC86,625$96.2K0.0%−365
Vanguard Fiduciary Trust Co68,908$76.5K0.0%No change
BlackRock, Inc.39,068$43.4K0.0%No change
Squarepoint Ops LLC30,900$34.3K0.0%New
Northern Trust Corp20,136$22.4K0.0%+6,083
Citadel Advisors LLC19,820$22.0K0.0%New
UBS Group AG5,636$6.3K0.0%+1,103
Tower Research Capital LLC (TRC)3,922$4.4K0.0%+1,132
Morgan Stanley2,022$2.2K0.0%−36
Osaic Holdings, Inc.1,513$1.7K0.0%−16
Federation des caisses Desjardins du Quebec292$3240.0%No change
Jones Financial Companies Lllp239$2580.0%No change
Barclays PLC222$2460.0%New
SBI Securities Co., Ltd.56$620.0%No change
Parallel Advisors, LLC18$200.0%No change
Bnp Paribas Financial Markets3$30.0%No change
Caitong International Asset Management Co., Ltd3$30.0%New
Royal Bank Of Canada28$00.0%+1

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78